when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Evkeeza

drug

evinacumab

Marketedupdated 3mo ago

by $REGN REGENERON PHARMACEUTICALS, INC.

Approved

community read0 votes

🐶 often sniffed alongside

top 2

drugEVKEEZA12 co-mentions · 3 sources
tagApproval12 co-mentions · 3 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

all catalysts(3)

approval · 3

$REGN826.64-1.69%

EVKEEZA (EVINACUMAB-DGNB) — FDA approval

$REGN826.64-1.69%

EVKEEZA (EVINACUMAB-DGNB) — FDA approval

$REGN826.64-1.69%

EVKEEZA (EVINACUMAB-DGNB) — FDA approval

Trials studying evinacumab

phase2Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Diseaserecruitingn=270
—Compassionate Use of Evinacumabapproved for marketing
phase3Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemiacompletedn=116
phase3Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemiacompletedn=10
phase3Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemiacompletedn=20
phase2Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitisterminatedn=21

News(0)

no news has mentioned this drug yet

brand

Evkeeza

generic

evinacumab-dgnb

MOA

12.1 Mechanism of Action Evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab-dgnb inhibition of ANGPTL3 leads to reduction in LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Evinacumab-dgnb reduces LDL-C independent of the presence of LDL receptor (LDLR) by promoting very low-density lipoprotein (VLDL) processing and clearance upstream of LDL formation. Evinacumab-dgnb blockade of ANGPTL3 lowers TG and HDL-C by rescuing LPL and EL activities, respectively.

indication

Homozygous Familial Hypercholesterolemia (HoFH)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 10m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?